What You Should Know:
– Helix, a leader in population genomics and precision health, and Komodo Health, a leader in healthcare technology and data-driven insights, are partnering to further enrich Helix’s clinico-genomic datasets within the Helix Research Network (HRN) for research and life science partners.
– The partnership will add insights derived from medical, pharmacy and mortality data from Komodo’s Healthcare Map®, the industry’s most robust and precise view of longitudinal de-identified patient-level insights.
Helix and Komodo Health Partner to Enhance Precision Medicine with Expanded Clinico-Genomic Insights
Helix, the leading organization in population genomics and precision health, is advancing the integration of genomic data into patient care and therapeutic development through a strategic partnership with Komodo Health. By combining Helix’s robust clinico-genomic dataset with Komodo’s Healthcare Map, this collaboration aims to deliver deeper insights into medication usage, treatment adherence, and the total cost of care across diverse conditions.
Enhancing Multimodal Data Depth for Research
The partnership builds on Helix’s growing Human Research Network (HRN), a dynamic and continuously expanding clinico-genomic registry. Key features include:
• Extensive Genomic Profiles: A repository of 500,000 whole-exome profiles, with a target to exceed 1.5 million participants from existing health system partnerships by the end of 2025.
• Data Integration: Regular electronic health record (EHR) updates across cohorts and the ability to recontact participants for future research opportunities.
• Multimodal Insights: Integration of Komodo’s data to explore patient responses to treatments and develop targeted profiles for therapeutic innovation.
HRN’s clinico-genomic database, already the largest hereditary genomic dataset in North America, is on track to become the largest globally by late 2025. Its dynamic design goes beyond static biobank databases by incorporating real-time updates and longitudinal data, offering researchers unparalleled depth and scope.
Empowering Drug Development and Precision Medicine
Through this collaboration, life sciences researchers gain access to actionable insights that inform all stages of the drug development lifecycle. The combined datasets enable a better understanding of treatment outcomes, optimized therapeutic development, and enhanced precision in targeted patient care.
Dr. James Lu, CEO and co-founder of Helix, emphasized the partnership’s significance: “Augmenting Helix data with Komodo’s Healthcare Map expands our ability to provide researchers with critical insights into treatment patterns and outcomes. This collaboration underscores Helix’s commitment to advancing precision medicine and supporting therapeutic innovation.”
By uniting genomic and healthcare data at scale, Helix and Komodo Health are setting a new standard for research capabilities, accelerating advancements in genomics-based medicine, and enabling more effective, patient-centered therapeutic solutions.
